287 related articles for article (PubMed ID: 19188571)
41. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
42. The blood-central nervous system barriers actively control immune cell entry into the central nervous system.
Engelhardt B
Curr Pharm Des; 2008; 14(16):1555-65. PubMed ID: 18673197
[TBL] [Abstract][Full Text] [Related]
43. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
Puñet-Ortiz J; Hervás-García JV; Teniente-Serra A; Cano-Orgaz A; Mansilla MJ; Quirant-Sánchez B; Navarro-Barriuso J; Fernández-Sanmartín MA; Presas-Rodríguez S; Ramo-Tello C; Martínez-Cáceres EM
Cytometry B Clin Cytom; 2018 Mar; 94(2):327-333. PubMed ID: 28378895
[TBL] [Abstract][Full Text] [Related]
44. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
Planas R; Jelčić I; Schippling S; Martin R; Sospedra M
Eur J Immunol; 2012 Mar; 42(3):790-8. PubMed ID: 22144343
[TBL] [Abstract][Full Text] [Related]
45. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
[TBL] [Abstract][Full Text] [Related]
46. Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4.
Shapiro RI; Plavina T; Schlain BR; Pepinsky RB; Garber EA; Jarpe M; Hochman PS; Wehner NG; Bard F; Motter R; Yednock TA; Taylor FR
J Pharm Biomed Anal; 2011 Apr; 55(1):168-75. PubMed ID: 21300512
[TBL] [Abstract][Full Text] [Related]
47. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.
Kivisäkk P; Healy BC; Viglietta V; Quintana FJ; Hootstein MA; Weiner HL; Khoury SJ
Neurology; 2009 Jun; 72(22):1922-30. PubMed ID: 19487650
[TBL] [Abstract][Full Text] [Related]
48. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
Stüve O; Cravens PD; Frohman EM; Phillips JT; Remington GM; von Geldern G; Cepok S; Singh MP; Tervaert JW; De Baets M; MacManus D; Miller DH; Radü EW; Cameron EM; Monson NL; Zhang S; Kim R; Hemmer B; Racke MK
Neurology; 2009 Feb; 72(5):396-401. PubMed ID: 18987352
[TBL] [Abstract][Full Text] [Related]
49. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
Foley J
Am J Manag Care; 2010 Jun; 16(6 Suppl):S178-83. PubMed ID: 20615054
[TBL] [Abstract][Full Text] [Related]
50. Immunotoxicity profile of natalizumab.
Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
[TBL] [Abstract][Full Text] [Related]
51. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
52. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
Davenport RJ; Munday JR
Drug Discov Today; 2007 Jul; 12(13-14):569-76. PubMed ID: 17631252
[TBL] [Abstract][Full Text] [Related]
53. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.
Jing D; Oelschlaegel U; Ordemann R; Hölig K; Ehninger G; Reichmann H; Ziemssen T; Bornhäuser M
Bone Marrow Transplant; 2010 Oct; 45(10):1489-96. PubMed ID: 20098455
[TBL] [Abstract][Full Text] [Related]
54. [Natalizumab in multiple sclerosis].
Rajda C; Bencsik K; Vécsei L;
Ideggyogy Sz; 2008 May; 61(5-6):204-8. PubMed ID: 18567397
[No Abstract] [Full Text] [Related]
55. Effects of natalizumab treatment on Foxp3+ T regulatory cells.
Stenner MP; Waschbisch A; Buck D; Doerck S; Einsele H; Toyka KV; Wiendl H
PLoS One; 2008 Oct; 3(10):e3319. PubMed ID: 18836525
[TBL] [Abstract][Full Text] [Related]
56. The discovery of natalizumab, a potent therapeutic for multiple sclerosis.
Steinman L
J Cell Biol; 2012 Oct; 199(3):413-6. PubMed ID: 23109666
[TBL] [Abstract][Full Text] [Related]
57. [Immunosuppression with monoclonal antibodies in multiple sclerosis].
Vermersch P; Zéphir H
Rev Neurol (Paris); 2007 Jun; 163(6-7):682-7. PubMed ID: 17607190
[TBL] [Abstract][Full Text] [Related]
58. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
Harrer A; Pilz G; Einhaeupl M; Oppermann K; Hitzl W; Wipfler P; Sellner J; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
PLoS One; 2012; 7(2):e31784. PubMed ID: 22363732
[TBL] [Abstract][Full Text] [Related]
59. alpha4-Integrin antagonism with natalizumab: effects and adverse effects.
Stüve O; Gold R; Chan A; Mix E; Zettl U; Kieseier BC
J Neurol; 2008 Dec; 255 Suppl 6():58-65. PubMed ID: 19300961
[TBL] [Abstract][Full Text] [Related]
60. To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.
Scarpazza C; Prosperini L; De Rossi N; Moiola L; Sormani MP; Gerevini S; Capra R;
Ann Neurol; 2017 Nov; 82(5):697-705. PubMed ID: 29023856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
